Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data
Authors
Keywords
-
Journal
OncoTargets and Therapy
Volume Volume 13, Issue -, Pages 12367-12382
Publisher
Informa UK Limited
Online
2020-12-01
DOI
10.2147/ott.s287944
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
- (2020) Ayalew Tefferi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
- (2020) Heinz Gisslinger et al. Lancet Haematology
- Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat
- (2020) Elisabeth Oppliger Leibundgut et al. HAEMATOLOGICA
- Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
- (2020) Onima Chowdhury et al. LEUKEMIA
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features
- (2020) Giacomo Coltro et al. Blood Advances
- Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation
- (2019) Nico Gagelmann et al. BLOOD
- Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants
- (2019) Christian Pecquet et al. BLOOD
- Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface
- (2019) Nami Masubuchi et al. LEUKEMIA
- Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms
- (2019) Paola Guglielmelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- Novel Drivers and Modifiers of MPL-dependent Oncogenic Transformation Identified by Deep Mutational Scanning
- (2019) Jessica L Bridgford et al. BLOOD
- JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2 V617F mutated disease
- (2018) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- The co-occurrence of driver mutations in chronic myeloproliferative neoplasms
- (2018) Prajwal Boddu et al. ANNALS OF HEMATOLOGY
- PPM1D truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells
- (2018) Josephine D. Kahn et al. BLOOD
- MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
- (2018) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
- (2018) Paola Guglielmelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
- (2018) Maura Nicolosi et al. LEUKEMIA
- Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
- (2018) Ayalew Tefferi et al. LEUKEMIA
- U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
- (2018) Ayalew Tefferi et al. LEUKEMIA
- Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
- (2018) Ayalew Tefferi et al. LEUKEMIA
- GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
- (2018) Ayalew Tefferi et al. LEUKEMIA
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
- (2018) Tiziano Barbui et al. LEUKEMIA
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients
- (2018) Andrew T. Kuykendall et al. AMERICAN JOURNAL OF HEMATOLOGY
- JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
- (2018) Julia Czech et al. LEUKEMIA
- Classification and Personalized Prognosis in Myeloproliferative Neoplasms
- (2018) Jacob Grinfeld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
- (2018) Annalisa Pacilli et al. Blood Cancer Journal
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
- (2017) Francesco Passamonti et al. LANCET ONCOLOGY
- The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders
- (2017) N Maslah et al. LEUKEMIA
- Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis
- (2017) A Tefferi et al. LEUKEMIA
- A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
- (2017) F Passamonti et al. LEUKEMIA
- Genetic Risk Assessment in Myeloproliferative Neoplasms
- (2017) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial
- (2017) Lucia Masarova et al. Lancet Haematology
- Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms
- (2016) Giuseppe Gaetano Loscocco et al. AMERICAN JOURNAL OF HEMATOLOGY
- Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients
- (2016) Mahnur Haider et al. AMERICAN JOURNAL OF HEMATOLOGY
- LNK mutations in familial myeloproliferative neoplasms
- (2016) Elisa Rumi et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
- (2016) A. Alvarez-Larran et al. HAEMATOLOGICA
- Loss ofEzh2synergizes withJAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
- (2016) Takafumi Shimizu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Thrombopoietin receptor is required for the oncogenic function of CALR mutants
- (2016) H Nivarthi et al. LEUKEMIA
- Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin
- (2016) T Balligand et al. LEUKEMIA
- JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy
- (2016) G Barosi et al. LEUKEMIA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
- (2016) Lasse Kjær et al. PLoS One
- Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation
- (2016) S. Elf et al. Cancer Discovery
- Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
- (2016) A. Alvarez-Larran et al. HAEMATOLOGICA
- Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b
- (2015) Nicole C.C. Them et al. AMERICAN JOURNAL OF HEMATOLOGY
- Clinical and molecular response to interferon- therapy in essential thrombocythemia patients with CALR mutations
- (2015) E. Verger et al. BLOOD
- Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
- (2015) J. D. Milosevic Feenstra et al. BLOOD
- Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
- (2015) I. Chachoua et al. BLOOD
- Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients
- (2015) X. Cabagnols et al. BLOOD
- Ropeginterferon alfa-2b, a novel IFN -2b, induces high response rates with low toxicity in patients with polycythemia vera
- (2015) H. Gisslinger et al. BLOOD
- DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
- (2015) J. Nangalia et al. HAEMATOLOGICA
- Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
- (2015) D Pietra et al. LEUKEMIA
- Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms
- (2015) J-P Defour et al. LEUKEMIA
- Co-existence ofJAK2V617F andCALRmutations in primary myelofibrosis
- (2015) Lurdes Zamora et al. LEUKEMIA & LYMPHOMA
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Mutation Order on Myeloproliferative Neoplasms
- (2015) Christina A. Ortmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
- (2015) Gabriela M. Baerlocher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis
- (2015) P Guglielmelli et al. Blood Cancer Journal
- Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
- (2015) S Cerquozzi et al. Blood Cancer Journal
- Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
- (2015) T Barbui et al. Blood Cancer Journal
- DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
- (2015) J. Nangalia et al. HAEMATOLOGICA
- Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
- (2014) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm
- (2014) V. Sangkhae et al. BLOOD
- The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants
- (2014) A. Tefferi et al. BLOOD
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
- (2014) A. Tefferi et al. BLOOD
- CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
- (2014) A Tefferi et al. LEUKEMIA
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
- (2014) A Tefferi et al. LEUKEMIA
- Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution
- (2014) X Cabagnols et al. LEUKEMIA
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
- (2014) P Guglielmelli et al. LEUKEMIA
- Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
- (2013) G. Rotunno et al. BLOOD
- JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
- (2013) E. Rumi et al. BLOOD
- Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon -2a
- (2013) A. Quintas-Cardama et al. BLOOD
- Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union
- (2013) Odile Moulard et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse
- (2013) T. Lange et al. HAEMATOLOGICA
- MPN patients harbor recurrent truncating mutations in transcription factor NF-E2
- (2013) Jonas S. Jutzi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
- (2012) S.-J. Zhang et al. BLOOD
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
- (2012) T. Barbui et al. BLOOD
- SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
- (2012) T. L. Lasho et al. BLOOD
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- The JAK2 exon 12 mutations: A comprehensive review
- (2011) Linda M. Scott AMERICAN JOURNAL OF HEMATOLOGY
- EZH2 mutational status predicts poor survival in myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
- (2011) F. Passamonti et al. BLOOD
- Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
- (2010) H. Alchalby et al. BLOOD
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
- (2010) A Tefferi et al. LEUKEMIA
- Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
- (2010) D Caramazza et al. LEUKEMIA
- Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2 V617F clones without affecting TET2 mutant cells
- (2010) J-J Kiladjian et al. LEUKEMIA
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Advances in Understanding and Management of Myeloproliferative Neoplasms
- (2009) A. M. Vannucchi et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Calreticulin: non-endoplasmic reticulum functions in physiology and disease
- (2009) Leslie I. Gold et al. FASEB JOURNAL
- Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
- (2009) Masashi Sanada et al. NATURE
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Targeting Ras in Myeloid Leukemias
- (2008) B. S. Braun et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started